trending Market Intelligence /marketintelligence/en/news-insights/trending/vKFgLMQ8zkDQYRm_SYa0vg2 content esgSubNav
In This List

Assembly Biosciences prices $125M stock, warrants offering to fund research


Baird Research is Now Exclusively Available in S&P Global’s Aftermarket Research Collection


Japan M&A By the Numbers: Q4 2023


Essential IR Insights Newsletter Fall - 2023

Case Study

A Corporation Clearly Pinpoints Activist Investor Activity

Assembly Biosciences prices $125M stock, warrants offering to fund research

Assembly Biosciences Inc. priced a common stock and warrants offering to raise about $125 million in gross proceeds.

The Carmel, Ind.-based biotechnology company priced the public offering of 5,151,515 common shares at $16.50 apiece.

In addition, Assembly is also offering pre-funded warrants to a certain existing investor to buy up to 2,424,242 common shares at $16.499 per pre-funded warrant.

Jefferies LLC, SVB Leerink LLC and William Blair & Co. LLC are serving as joint book-running managers, while Mizuho Securities USA LLC and Robert W. Baird & Co. Inc. are acting as co-managers for the offering.

The company granted the underwriters a 30-day option to buy up to an additional 1,136,363 shares for $16.50 each.

Assembly plans to use the net proceeds from the sale of the common stock to fund clinical trials, nonclinical studies, research and development and for general corporate purposes.

The offering is expected to close around Dec. 16, subject to customary closing conditions.